{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T19:02:26Z","timestamp":1773342146940,"version":"3.50.1"},"reference-count":80,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Preterm birth is a leading cause of neonatal mortality and long-term disability worldwide. Injury in premature infants is demonstrated by disrupted organ development from inflammation, oxidative stress, hypoxia, and impaired vascular maturation. Current therapies largely provide supportive care and do not directly promote tissue regeneration. Mesenchymal stem cell (MSC)-based therapies have emerged as a potential strategy to enhance endogenous repair across organ systems commonly affected by prematurity. Results: Evidence indicates that MSCs exert therapeutic effects primarily through transient paracrine signaling rather than long-term engraftment. Following administration, MSCs release cytokines, growth factors, and extracellular vesicles that reduce inflammation, promote angiogenesis, and support tissue repair. In preclinical models of neonatal brain injury, MSC therapy has been associated with improved oligodendrocyte maturation and reduced white matter injury. Early clinical trials in neonatal encephalopathy demonstrate feasibility and short-term safety of both autologous and allogeneic cell products. However, studies remain limited by small sample sizes and short follow-up. Cell-free approaches using MSC-derived extracellular vesicles may offer similar biological benefits with potentially lower safety and regulatory concerns. Conclusions: MSC-based therapies represent a promising regenerative approach for complications of prematurity. Rigorous, large-scale trials with standardized protocols and long-term follow-up are necessary to clarify efficacy, optimize delivery strategies, and define safety in this vulnerable population.<\/jats:p>","DOI":"10.3390\/ph19030464","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:23:03Z","timestamp":1773307383000},"page":"464","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mesenchymal Stem Cell Therapy for Neurological Complications of Prematurity: A Narrative Review"],"prefix":"10.3390","volume":"19","author":[{"given":"Hua (Hannah)","family":"Yep","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9640-1547","authenticated-orcid":false,"given":"Jennifer H.","family":"Bae","sequence":"additional","affiliation":[{"name":"Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8732-5833","authenticated-orcid":false,"given":"George A.","family":"Wen","sequence":"additional","affiliation":[{"name":"Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangel","family":"Gomez","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Tsivitis","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9209-0389","authenticated-orcid":false,"given":"Robert P.","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5226-1921","authenticated-orcid":false,"given":"Helen","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Department of Surgery, Stony Brook University Hospital, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5641-5908","authenticated-orcid":false,"given":"Sergio D.","family":"Bergese","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Stony Brook University Hospital, Stony Brook, NY 11794, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12978-025-02033-x","article-title":"Born Too Soon: Global Epidemiology of Preterm Birth and Drivers for Change","volume":"22","author":"Bradley","year":"2025","journal-title":"Reprod. Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2445871","DOI":"10.1001\/jamanetworkopen.2024.45871","article-title":"Short-Term and Long-Term Mortality Risk After Preterm Birth","volume":"7","author":"Ahmed","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"101322","DOI":"10.1016\/j.siny.2021.101322","article-title":"Placental Tissue Stem Cells and Their Role in Neonatal Diseases","volume":"27","author":"Damianos","year":"2022","journal-title":"Semin. Fetal. Neonatal Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101325","DOI":"10.1016\/j.siny.2022.101325","article-title":"Stem Cells in Neonatal Diseases: An Overview","volume":"27","author":"Chaubey","year":"2022","journal-title":"Semin. Fetal. Neonatal Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/bs.pmbts.2023.02.012","article-title":"Introduction to Stem Cells","volume":"199","author":"Tian","year":"2023","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_6","first-page":"919","article-title":"Stem Cell: Basics, Classification and Applications","volume":"2","author":"Kalra","year":"2014","journal-title":"Am. J. Phytomed. Clin. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.stem.2020.09.014","article-title":"Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges","volume":"27","author":"Yamanaka","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_8","first-page":"1273","article-title":"Serial Transplantation Reveals the Stem-Cell-like Regenerative Potential of Adult Mouse Hepatocytes","volume":"151","author":"Overturf","year":"1997","journal-title":"Am. J. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ydbio.2020.12.010","article-title":"Modeling Human Embryo Development with Embryonic and Extra-Embryonic Stem Cells","volume":"474","author":"Weatherbee","year":"2021","journal-title":"Dev. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Priester, C., MacDonald, A., Dhar, M., and Bow, A. (2020). Examining the Characteristics and Applications of Mesenchymal, Induced Pluripotent, and Embryonic Stem Cells for Tissue Engineering Approaches across the Germ Layers. Pharmaceuticals, 13.","DOI":"10.3390\/ph13110344"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10565-017-9384-y","article-title":"Clinical Potentials of Human Pluripotent Stem Cells","volume":"33","author":"Mora","year":"2017","journal-title":"Cell Biol. Toxicol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/stem.2450","article-title":"Concise Review: Human Embryonic Stem Cells\u2014What Have We Done? What Are We Doing? Where Are We Going?","volume":"35","author":"Ilic","year":"2017","journal-title":"Stem Cells"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1177\/0192623320918241","article-title":"Accept or Reject: The Role of Immune Tolerance in the Development of Stem Cell Therapies and Possible Future Approaches","volume":"49","author":"Haworth","year":"2021","journal-title":"Toxicol. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejmg.2017.10.015","article-title":"Epigenetic Changes in Mesenchymal Stem Cells Differentiation","volume":"61","author":"Mortada","year":"2018","journal-title":"Eur. J. Med. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/term.2914","article-title":"Mesenchymal Stem Cells: Cell Therapy and Regeneration Potential","volume":"13","author":"Brown","year":"2019","journal-title":"J. Tissue Eng. Regen. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lohan, P., Treacy, O., Griffin, M.D., Ritter, T., and Ryan, A.E. (2017). Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning?. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01626"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Liau, L.L., Al-Masawa, M.E., Koh, B., Looi, Q.H., Foo, J.B., Lee, S.H., Cheah, F.C., and Law, J.X. (2020). The Potential of Mesenchymal Stromal Cell as Therapy in Neonatal Diseases. Front. Pediatr., 8.","DOI":"10.3389\/fped.2020.591693"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Vizoso, F.J., Eiro, N., Cid, S., Schneider, J., and Perez-Fernandez, R. (2017). Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091852"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"BSR20200241","DOI":"10.1042\/BSR20200241","article-title":"Mesenchymal Stem Cell-Derived Secretomes for Therapeutic Potential of Premature Infant Diseases","volume":"40","author":"Wang","year":"2020","journal-title":"Biosci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1055\/s-0039-1691774","article-title":"Stem Cells for Extreme Prematurity","volume":"36","year":"2019","journal-title":"Am. J. Perinatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41392-024-01936-8","article-title":"Pharmacokinetic Characteristics of Mesenchymal Stem Cells in Translational Challenges","volume":"9","author":"Shan","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-022-00932-0","article-title":"The Secretion Profile of Mesenchymal Stem Cells and Potential Applications in Treating Human Diseases","volume":"7","author":"Han","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/stem.2779","article-title":"Immunomodulation by Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC by Monocytic Cells","volume":"36","author":"Luk","year":"2018","journal-title":"Stem Cells"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/sctm.18-0024","article-title":"Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise","volume":"7","author":"Krueger","year":"2018","journal-title":"Stem Cells Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"114191","DOI":"10.1016\/j.biopha.2022.114191","article-title":"Fate of Intravenously Administered Umbilical Cord Mesenchymal Stromal Cells and Interactions with the Host\u2019s Immune System","volume":"159","author":"Amadeo","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/stem.1118","article-title":"Analysis of Tissues Following Mesenchymal Stromal Cell Therapy in Humans Indicates Limited Long-Term Engraftment and No Ectopic Tissue Formation","volume":"30","author":"Batsis","year":"2012","journal-title":"Stem Cells"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/pr.2017.249","article-title":"Strategies to Enhance Paracrine Potency of Transplanted Mesenchymal Stem Cells in Intractable Neonatal Disorders","volume":"83","author":"Park","year":"2018","journal-title":"Pediatr. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"H112","DOI":"10.1152\/ajpheart.00217.2021","article-title":"Current Status of Myocardial Restoration via the Paracrine Function of Mesenchymal Stromal Cells","volume":"321","author":"Hematti","year":"2021","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.ymthe.2020.05.022","article-title":"Macrophage Subpopulation Dynamics Shift Following Intravenous Infusion of Mesenchymal Stromal Cells","volume":"28","author":"Kosaric","year":"2020","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jcyt.2017.03.075","article-title":"Mesenchymal Stromal Cells from Umbilical Cord Wharton\u2019s Jelly Trigger Oligodendroglial Differentiation in Neural Progenitor Cells through Cell-to-Cell Contact","volume":"19","author":"Oppliger","year":"2017","journal-title":"Cytotherapy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s12015-021-10321-9","article-title":"Distinct Effects of the Hippocampal Transplantation of Neural and Mesenchymal Stem Cells in a Transgenic Model of Alzheimer\u2019s Disease","volume":"18","author":"Campos","year":"2022","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41419-021-03839-w","article-title":"Short Lifespan of Syngeneic Transplanted MSC Is a Consequence of in Vivo Apoptosis and Immune Cell Recruitment in Mice","volume":"12","author":"Preda","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41392-021-00688-z","article-title":"Spontaneous Apoptosis of Cells in Therapeutic Stem Cell Preparation Exert Immunomodulatory Effects through Release of Phosphatidylserine","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41392-025-02312-w","article-title":"Extracellular Vesicle-Based Drug Overview: Research Landscape, Quality Control and Nonclinical Evaluation Strategies","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100034","DOI":"10.1016\/j.vesic.2024.100034","article-title":"Understanding Molecular Characteristics of Extracellular Vesicles Derived from Different Types of Mesenchymal Stem Cells for Therapeutic Translation","volume":"3","author":"Ding","year":"2024","journal-title":"Extracell. Vesicle"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41419-022-05034-x","article-title":"Mesenchymal Stem Cell-Derived Extracellular Vesicles for Immunomodulation and Regeneration: A next Generation Therapeutic Tool?","volume":"13","author":"Kou","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Li, S., Zhang, J., Sun, L., Yang, Z., Liu, X., Liu, J., and Liu, X. (2025). Mesenchymal Stem Cell-Derived Extracellular Vesicles: Current Advances in Preparation and Therapeutic Applications for Neurological Disorders. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1626996"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"114616","DOI":"10.1016\/j.yexcr.2025.114616","article-title":"Mesenchymal Stem Cell-Derived Exosomes: A Paradigm Shift in Clinical Therapeutics","volume":"450","author":"Chattopadhyay","year":"2025","journal-title":"Exp. Cell Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"102715","DOI":"10.1016\/j.omtn.2025.102715","article-title":"miRNAs from Mesenchymal-Stem-Cell-Derived Extracellular Vesicles: Emerging Players in Regenerative Medicine and Disease Therapy","volume":"36","author":"Shahsavandi","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Fu, Y., Yang, L., Lan, S., Zhang, S., Zhang, K., Bai, S., Qin, W., Zheng, C., Sui, B., and Fu, Y. (2025). Mesenchymal Stem Cell-Derived Extracellular Vesicles in Therapeutic Use. Mesenchymal Stem Cells\u2014Biology, Therapeutics, and Beyond, IntechOpen.","DOI":"10.5772\/intechopen.1011445"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Wong, C., Stoilova, I., Gazeau, F., Herbeuval, J.-P., and Fourniols, T. (2024). Mesenchymal Stromal Cell Derived Extracellular Vesicles as a Therapeutic Tool: Immune Regulation, MSC Priming, and Applications to SLE. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1355845"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12951-024-02304-y","article-title":"Mesenchymal Stem Cell-Derived Extracellular Vesicles Exert pro-Angiogenic and pro-Lymphangiogenic Effects in Ischemic Tissues by Transferring Various microRNAs and Proteins Including ITGa5 and NRP1","volume":"22","author":"Vergori","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12967-024-05282-9","article-title":"Mesenchymal Stromal Cell-Derived Extracellular Vesicles Therapy Openings New Translational Challenges in Immunomodulating Acute Liver Inflammation","volume":"22","author":"Sitbon","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e12433","DOI":"10.1002\/jev2.12433","article-title":"Extracellular Vesicles as Human Therapeutics: A Scoping Review of the Literature","volume":"13","author":"Fusco","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13578-021-00698-y","article-title":"Allogeneic vs. Autologous Mesenchymal Stem\/Stromal Cells in Their Medication Practice","volume":"11","author":"Li","year":"2021","journal-title":"Cell Biosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s13287-025-04438-8","article-title":"Pharmacological Modulation of Stem Cells Signaling Pathway for Therapeutic Applications","volume":"16","author":"Alnasser","year":"2025","journal-title":"Stem Cell Res. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Parrotta, E.I., Scalise, S., Scaramuzzino, L., and Cuda, G. (2019). Stem Cells: The Game Changers of Human Cardiac Disease Modelling and Regenerative Medicine. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225760"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8840","DOI":"10.7150\/thno.120805","article-title":"Modulation of Stem Cell Survival and Engraftment: Implications for Stem Cell-Based Therapy","volume":"15","author":"Xu","year":"2025","journal-title":"Theranostics"},{"key":"ref_49","first-page":"343","article-title":"Increased Knee Cartilage Volume in Degenerative Joint Disease Using Percutaneously Implanted, Autologous Mesenchymal Stem Cells","volume":"11","author":"Centeno","year":"2008","journal-title":"Pain Physician"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Follicular Lymphoma","volume":"102","author":"Loberiza","year":"2003","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/00041552-200307000-00014","article-title":"Stem Cell Biology and Therapeutic Applications","volume":"12","author":"Garry","year":"2003","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1532-950X.2005.00063.x","article-title":"Stem Cells: Classifications, Controversies, and Clinical Applications","volume":"34","author":"Fortier","year":"2005","journal-title":"Vet. Surg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41408-024-01067-x","article-title":"Factors Determining Utilization of Stem Cell Transplant for Initial Therapy of Multiple Myeloma by Patient Race: Exploring Intra-Racial Healthcare Disparities","volume":"14","author":"Ailawadhi","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e29099","DOI":"10.1002\/pbc.29099","article-title":"Decision Making for Hematopoietic Stem Cell Transplantation in Pediatric, Adolescent, and Young Adult Patients with a Hemoglobinopathy-Shared or Not?","volume":"68","author":"Mekelenkamp","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Mian, O., Puts, M., McCurdy, A., Wildes, T.M., Fiala, M.A., Kang, M., Salib, M., Alibhai, S., and Mian, H. (2023). Decision-Making Factors for an Autologous Stem Cell Transplant for Older Adults with Newly Diagnosed Multiple Myeloma: A Qualitative Analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.974038"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"van der Stoep, M.Y.E.C., Oostenbrink, L.V.E., Bredius, R.G.M., Moes, D.J.A.R., Guchelaar, H.-J., Zwaveling, J., and Lankester, A.C. (2022). Therapeutic Drug Monitoring of Conditioning Agents in Pediatric Allogeneic Stem Cell Transplantation; Where Do We Stand?. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.826004"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.htct.2019.05.006","article-title":"Bacteremia in Pediatric Patients with Hematopoietic Stem Cell Transplantation","volume":"42","author":"Perez","year":"2020","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jtct.2023.08.028","article-title":"Overcoming Barriers to Autologous Stem Cell Transplantation in Multiple Myeloma: Recommendations from a Multidisciplinary Roundtable Discussion","volume":"29","author":"Bashir","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s13287-022-02973-2","article-title":"Clinical Trials of Stem Cell-Based Therapies for Pediatric Diseases: A Comprehensive Analysis of Trials Registered on ClinicalTrials.Gov and the ICTRP Portal Site","volume":"13","author":"Ji","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.spen.2009.09.005","article-title":"The Encephalopathy of Prematurity\u2014Brain Injury and Impaired Brain Development Inextricably Intertwined","volume":"16","author":"Volpe","year":"2009","journal-title":"Semin. Pediatr. Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ca.22430","article-title":"The Neuroanatomy of Prematurity: Normal Brain Development and the Impact of Preterm Birth","volume":"28","author":"Ortinau","year":"2015","journal-title":"Clin. Anat."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/glia.23919","article-title":"Intranasal Mesenchymal Stem Cell Therapy to Boost Myelination after Encephalopathy of Prematurity","volume":"69","author":"Vaes","year":"2021","journal-title":"Glia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13287-015-0111-4","article-title":"White Matter Injury Restoration after Stem Cell Administration in Subcortical Ischemic Stroke","volume":"6","author":"Fuentes","year":"2015","journal-title":"Stem Cell Res. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Donega, V., Nijboer, C.H., Braccioli, L., Slaper-Cortenbach, I., Kavelaars, A., van Bel, F., and Heijnen, C.J. (2014). Intranasal Administration of Human MSC for Ischemic Brain Injury in the Mouse: In Vitro and in Vivo Neuroregenerative Functions. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0112339"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1007\/s12015-025-10905-9","article-title":"Translational Potential of Stem Cell-Based Therapies in the Treatment of Neonatal Hypoxic-Ischemic Brain Injury","volume":"21","author":"Gebala","year":"2025","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jpeds.2013.11.036","article-title":"Feasibility of Autologous Cord Blood Cells for Infants with Hypoxic-Ischemic Encephalopathy","volume":"164","author":"Cotten","year":"2014","journal-title":"J. Pediatr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1038\/s41598-020-61311-9","article-title":"Autologous Cord Blood Cell Therapy for Neonatal Hypoxic-Ischaemic Encephalopathy: A Pilot Study for Feasibility and Safety","volume":"10","author":"Tsuji","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/stcltm\/szad027","article-title":"A Pilot Phase I Trial of Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells in Neonates with Hypoxic-Ischemic Encephalopathy","volume":"12","author":"Cotten","year":"2023","journal-title":"Stem Cells Transl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"151731","DOI":"10.1016\/j.semperi.2023.151731","article-title":"Barriers in Translating Stem Cell Therapies for Neonatal Diseases","volume":"47","author":"Damianos","year":"2023","journal-title":"Semin. Perinatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"114349","DOI":"10.4252\/wjsc.v17.i12.114349","article-title":"Hurdles to Overcome for Mesenchymal Stem Cell Translation from Bench to Bedside","volume":"17","author":"Mayeen","year":"2025","journal-title":"World J. Stem Cells"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/med.22002","article-title":"Translating Mesenchymal Stem Cell and Their Exosome Research into GMP Compliant Advanced Therapy Products: Promises, Problems and Prospects","volume":"44","author":"Ma","year":"2024","journal-title":"Med. Res. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/sctm.19-0044","article-title":"Challenges in Clinical Development of Mesenchymal Stromal\/Stem Cells: Concise Review","volume":"8","author":"Mastrolia","year":"2019","journal-title":"Stem Cells Transl. Med."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Patel, J.C., Shukla, M., and Shukla, M. (2025). From Bench to Bedside: Translating Mesenchymal Stem Cell Therapies through Preclinical and Clinical Evidence. Front. Bioeng. Biotechnol., 13.","DOI":"10.3389\/fbioe.2025.1639439"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Johnson, J., Shojaee, M., Mitchell Crow, J., and Khanabdali, R. (2021). From Mesenchymal Stromal Cells to Engineered Extracellular Vesicles: A New Therapeutic Paradigm. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.705676"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/sctm.21-0021","article-title":"Advances in Mesenchymal Stem Cell Therapy for Immune and Inflammatory Diseases: Use of Cell-Free Products and Human Pluripotent Stem Cell-Derived Mesenchymal Stem Cells","volume":"10","author":"Wang","year":"2021","journal-title":"Stem Cells Transl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"176719","DOI":"10.1016\/j.ejphar.2024.176719","article-title":"Mesenchymal Stem Cells Biological and Biotechnological Advances: Implications for Clinical Applications","volume":"977","author":"Pharoun","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jcyt.2023.09.001","article-title":"Failure to Launch Commercially-Approved Mesenchymal Stromal Cell Therapies: What\u2019s the Path Forward? Proceedings of the International Society for Cell & Gene Therapy (ISCT) Annual Meeting Roundtable Held in May 2023, Palais Des Congr\u00e8s de Paris, Organized by the ISCT MSC Scientific Committee","volume":"26","author":"Robb","year":"2024","journal-title":"Cytotherapy"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.jcyt.2025.04.062","article-title":"Evaluating Teratoma Formation Risk of Pluripotent Stem Cell-Derived Cell Therapy Products: A Consensus Recommendation from the Health and Environmental Sciences Institute\u2019s International Cell Therapy Committee","volume":"27","author":"Watanabe","year":"2025","journal-title":"Cytotherapy"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1186\/s13287-021-02609-x","article-title":"The Safety of MSC Therapy over the Past 15 Years: A Meta-Analysis","volume":"12","author":"Wang","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Matsuoka, T., Itohara, T., Hara, Y., and Kobayashi, N. (2024). Systematic Intravenous Administration of Autologous Mesenchymal Stem Cells Is Safe. J. Clin. Med., 13.","DOI":"10.20944\/preprints202410.2515.v1"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/3\/464\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:49:25Z","timestamp":1773308965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/3\/464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":80,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ph19030464"],"URL":"https:\/\/doi.org\/10.3390\/ph19030464","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]}}}